Market Cap
$24.9B
INSM
INSMED Inc
$111.12 ▲ +2.33%
Prev close $108.59Market cap$24.9B
ConsensusStrong Buy
12-mo target$197.74 (+78.0%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)37 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on INSM right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (97%)
Inst. Holders
50 funds
Inst. Value
$17.8B
Inst. Activity
37 buys / 13 sells
Insider Activity
$0.00 buy / $53.5M sell
Insider Net $
-$53.5M
Social Sentiment
75° Bullish
SEC Reports
18
Congressional
1 trades
Price chart 30d -12.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 clinical_trial_readout
T-90d Trial Readout: Treprostinil Palmitil (Phase 3)
Trial: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial H
Sep 9, 2026 Insider
Aug 20, 2026 SEC Brennan David R sold 25,000 shares
Director @ $124.00 ($3.1M)
Two Insmed insiders sold a total of $32.6M in stock over the past week, including COO Roger Adsett's $31.96M sale and Di
CLUSTER — Impact 4/10
Aug 17, 2026 Insider
Aug 12, 2026 SEC SHAROKY MELVIN MD sold 5,000 shares
Director @ $127.53 ($637.6K)
Insmed's COO and CMO sold a combined $33.1M in stock immediately following a blockbuster Q2 earnings beat (revenue $425.
CLUSTER — Impact 4/10
Aug 10, 2026 Insider
Jul 21, 2026 SEC Adsett Roger acquired via exercise 76,600 shares
Chief Operating Officer @ $17.16 ($1.3M)
BMO Capital initiates INSM at Outperform — PT $192 (+78.6%)
ANALYST-UPGRADE — Impact 4/10
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — TRIM
10,428,170 shares ($1.1B)
Analyst ratings buy % +5.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
97% rate it Buy or better · 30 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Sep 15, 2026 | Roth Capital | REITERATE | Buy | 56% |
| Aug 10, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 10, 2026 | Truist Securities | REITERATE | Buy | 55% |
| Aug 7, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 7, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 7, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Jul 21, 2026 | BMO Capital | INITIATE | Outperform | 53% |
| Jul 15, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 10, 2026 | Guggenheim | REITERATE | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 20 | 1 | 0 | 0 | 97% | |
| Aug 1, 2026 | 9 | 20 | 1 | 0 | 0 | 97% | |
| Jul 1, 2026 | 9 | 19 | 1 | 0 | 0 | 97% | |
| Jun 1, 2026 | 9 | 19 | 1 | 0 | 0 | 97% | |
| May 1, 2026 | 9 | 18 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 9 | 16 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 9 | 16 | 2 | 0 | 0 | 93% |
Price targets
Where 23 covering analysts think INSM trades over the next 12 months.
$197.74 +78.0% upside Strong Buy
Current$111.12 Low$169.00 Median$195.00 High$243.00 23 analysts
$169.00$243.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Social media sentiment mood -16.4%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
75°
Bullish
BearishNeutralBullish
Recent posts
Nasdaq 100 Profit margins before and after new inclusions
▲ 1 · 💬 0· ⚡ 0.5
Nasdaq-100 Index Quarterly Changes - Added: Astera Labs, Inc., CoreWeave, Inc., Nebius Group N.V., Rocket Lab Corporation, Teradyne, Inc.
▲ 1 · 💬 0· ⚡ 0.5
NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
▲ 1 · 💬 0· ⚡ 0.5
NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
▲ 1 · 💬 0· ⚡ 0.5
19 MAY 2026, WHAT ARE THE BIGGEST LOSERS AND WHY ?
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 4 bullish, 3 bearish, 0 mixed, 11 neutral · avg impact 4.2/10.
BULLISHANALYST-UPGRADE4/10
BMO Capital initiates INSM at Outperform — PT $192 (+78.6%)
Jul 21, 2026
NEUTRALCLUSTER4/10
Two Insmed insiders sold a total of $32.6M in stock over the past week, including COO Roger Adsett's
Aug 20, 2026
NEUTRALCLUSTER4/10
Insmed's COO and CMO sold a combined $33.1M in stock immediately following a blockbuster Q2 earnings
Aug 12, 2026
BULLISH8-K8/10
Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estimates of $393.4M, driven by a 49%
Aug 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: Treprostinil Palmitil (Phase 3)
Trial: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) Sponsor: Insmed Incorporated Pha
Sep 30, 2026
Clinical Trial
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Phase Phase 2 — COMPLETED
Sep 21, 2026
short_volume
Short Volume: INSM — 60.8% short (0.5M / 0.9M)
Short: 544,852 | Exempt: 0 | TRF Vol: 896,382 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: INSM — 69.5% short (0.7M / 1.1M)
Short: 748,938 | Exempt: 0 | TRF Vol: 1,076,883 | Short Ratio: 69.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.36 | $-0.90–$0.04 | 79.2% | -1.0% | 12↑ 1↓ | $0.5B | 17 |
| Next Q | $-0.30 | $-1.12–$0.35 | 80.6% | +2.1% | 10↑ 2↓ | $0.6B | 17 |
| Current FY | $-1.54 | $-2.65–$-0.43 | 75.9% | +0.6% | 15↑ 0↓ | $1.8B | 18 |
| Next FY | $0.77 | $-0.91–$2.91 | 150.2% | -3.4% | 13↑ 3↓ | $2.9B | 18 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.365 | — |
| 7d ago | $-0.359 | -0.006 |
| 30d ago | $-0.361 | -0.004 |
| 60d ago | $-0.604 | +0.239 |
| 90d ago | $-0.610 | +0.246 |
Institutional ownership
Which big funds own INSM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $17.8B total value (166,996,798 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, VANGUARD. Net buying activity: 37 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 16,143,583 | $1.7B | 9.7% | — |
| BlackRock, Inc. | 15,807,984 | $1.7B | 9.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10,407,962 | $1.1B | 6.2% | — |
| JPMORGAN CHASE & CO | 10,428,170 | $1.1B | 6.1% | TRIM -56.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 9,790,865 | $1.0B | 5.9% | — |
| BAKER BROS. ADVISORS LP | 8,796,111 | $937.8M | 5.3% | — |
| Capital International Investors | 8,238,124 | $878.3M | 4.9% | ADD +47.2% |
| AMERIPRISE FINANCIAL INC | 6,179,571 | $658.9M | 3.7% | DOUBLED +102.1% |
| Orbis Allan Gray Ltd | 6,076,487 | $647.9M | 3.6% | DOUBLED +224.5% |
| STATE STREET CORP | 6,052,174 | $645.3M | 3.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | TRIM | 24,150,499 | 10,428,170 | -56.8% | $1.1B |
| Capital International Investors | ADD | 5,595,194 | 8,238,124 | +47.2% | $878.3M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 3,057,718 | 6,179,571 | +102.1% | $658.9M |
| Orbis Allan Gray Ltd | DOUBLED | 1,872,824 | 6,076,487 | +224.5% | $647.9M |
| NORGES BANK | NEW | — | 3,377,641 | — | $360.1M |
| UBS Group AG | ADD | 1,737,481 | 2,584,446 | +48.7% | $275.6M |
| MAVERICK CAPITAL LTD | NEW | — | 2,150,762 | — | $229.3M |
| MILLENNIUM MANAGEMENT LLC | ADD | 1,157,786 | 2,048,005 | +76.9% | $218.4M |
| Qube Research & Technologies Ltd | DOUBLED | 148,515 | 1,682,334 | +1032.8% | $179.4M |
| GOLDMAN SACHS GROUP INC | ADD | 942,646 | 1,409,885 | +49.6% | $150.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$53.5M — $0.00 bought, $53.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Brennan David R | Director | SELL | 25,000 | $124.00 | $3.1M |
| Aug 17, 2026 | SHAROKY MELVIN MD | Director | SELL | 5,000 | $127.53 | $637.6K |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | EXERCISE | 76,600 | $17.16 | $1.3M |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | EXERCISE | 80,970 | $30.46 | $2.5M |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | SELL | 239,850 | $133.27 | $32.0M |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | EXERCISE | 82,280 | $13.67 | $1.1M |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 8,895 | $127.00 | $1.1M |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | EXERCISE | 18,278 | $18.95 | $346.4K |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 18,278 | $129.40 | $2.4M |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | EXERCISE | 8,895 | $25.83 | $229.8K |
Congressional trades
INSM trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Josh Gottheimer | D | HOUSE | SELL | $1,001 - $15,000 | INSMED INC | Jul 8, 2026(29d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INSM.
Shares short
10,802,070
Settlement Sep 15, 2026
Change vs prior
-5.6%
Semi-monthly cycle
Days to cover
5.3
At avg daily volume
Of shares outstanding
≈5.0%
Estimate — not % of float
All INSM filing & press-release reports (18)
- BMO Capital initiates INSM at Outperform — PT $192 (+78.6%)Jul 21, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 12, 2026
- 8-K reportAug 6, 2026
- INST-CLUSTER reportJul 24, 2026
- 8-K reportJul 16, 2026
- CLUSTER reportJun 26, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportJun 5, 2026
- S-3ASR reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- 144 reportMay 13, 2026
- CLUSTER reportMay 13, 2026
- 8-K reportMay 7, 2026
- CLUSTER reportApr 8, 2026
- 8-K reportApr 7, 2026
- CLUSTER reportApr 3, 2026
- DEFA14A reportApr 1, 2026